Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu-177 PSMA-0057
- Development stage
- Phase 2
- Lead developer
- Suzhou Ruihe Pharmaceutical Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Lutetium Lu-177 PSMA-0057 is an investigational radioligand therapy (RLT) developed by Suzhou Ruihe Pharmaceutical Technology for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). The drug consists of the beta-emitting radioisotope lutetium-177 conjugated to the PSMA-0057 ligand, which specifically targets PSMA, a protein highly expressed on the surface of prostate cancer cells. Upon binding, the compound is internalized, delivering localized ionizing radiation to induce DNA damage and cell death in tumor cells while minimizing exposure to healthy tissue. It is typically paired with the diagnostic imaging agent Gallium [68Ga] PSMA-0057 as part of a theranostic approach.
- Other names
- Lutetium [177Lu] PSMA-0057177Lu-PSMA-0057
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium Lu-177 PSMA-0057.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu-177 PSMA-0057.